This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

. 2001 Oct;3(5):224-225.

doi: 10.4088/pcc.v03n0507a.

Dosing of Selective Serotonin Reuptake Inhibitors

Affiliations

PMID: 15014578
PMCID: PMC181220
DOI: 10.4088/pcc.v03n0507a

Dosing of Selective Serotonin Reuptake Inhibitors

Henry Chung. Prim Care Companion J Clin Psychiatry. 2001 Oct.

. 2001 Oct;3(5):224-225.

doi: 10.4088/pcc.v03n0507a.

Author

Affiliation

¹ Pfizer Inc, New York, New York.

PMID: 15014578
PMCID: PMC181220
DOI: 10.4088/pcc.v03n0507a

No abstract available

PubMed Disclaimer

Similar articles

Case-Control Study Examining the Association between Selective Serotonin Reuptake Inhibitors Use and Hepatocellular Carcinoma.
Lai SW, Liao KF, Lin CL, Lin HF. Lai SW, et al. Front Pharmacol. 2017 Nov 22;8:861. doi: 10.3389/fphar.2017.00861. eCollection 2017. Front Pharmacol. 2017. PMID: 29213242 Free PMC article.
Risk of Hip Fracture in Older People Using Selective Serotonin Reuptake Inhibitors and Other Psychoactive Medicines Concurrently: A Matched Case-Control Study in Australia.
Leach MJ, Pratt NL, Roughead EE. Leach MJ, et al. Drugs Real World Outcomes. 2017 Jun;4(2):87-96. doi: 10.1007/s40801-017-0107-8. Drugs Real World Outcomes. 2017. PMID: 28516333 Free PMC article.
Relationship between Recurrent Falls and Medication Use during Acute-Care Hospitalization: A Retrospective Descriptive Study.
Hirai T, Ishikawa Y, Kawagoe Y, Ogawa Y, Ogawa R, Itoh T. Hirai T, et al. Biol Pharm Bull. 2019;42(7):1192-1198. doi: 10.1248/bpb.b19-00116. Biol Pharm Bull. 2019. PMID: 31257294
Serotonin and Norepinephrine Reuptake Inhibitors.
Shelton RC. Shelton RC. Handb Exp Pharmacol. 2019;250:145-180. doi: 10.1007/164_2018_164. Handb Exp Pharmacol. 2019. PMID: 30838456
Selective serotonin reuptake inhibitors and Alzheimer's disease.
Mdawar B, Ghossoub E, Khoury R. Mdawar B, et al. Neural Regen Res. 2020 Jan;15(1):41-46. doi: 10.4103/1673-5374.264445. Neural Regen Res. 2020. PMID: 31535641 Free PMC article. Review.

See all similar articles

Cited by

Genetic and pharmacological manipulations of the serotonergic system in early life: neurodevelopmental underpinnings of autism-related behavior.
Kinast K, Peeters D, Kolk SM, Schubert D, Homberg JR. Kinast K, et al. Front Cell Neurosci. 2013 Jun 12;7:72. doi: 10.3389/fncel.2013.00072. eCollection 2013. Front Cell Neurosci. 2013. PMID: 23781172 Free PMC article.

References

1. Marken PA, Munro JS. Selecting a selective serotonin reuptake inhibitor: clinically important distinguishing features. Primary Care Companion J Clin Psychiatry. 2000;2:205–210. - PMC - PubMed
1. Cantrell R, Gillespie W, Altshuler L. Fluoxetine and sertraline dosages in major depression. Depress Anxiety. 1999;9:78–82. - PubMed
1. Fabre LF, Abuzzahab FS, Amin M, et al. Sertraline safety and efficacy in major depression: a double-blind fixed-dose comparison with placebo. Biol Psychiatry. 1995;38:592–602. - PubMed
1. Sheikh JI, Londborg P, Clary C, et al. The efficacy of sertraline in panic disorder: combined results from two fixed-dose studies. Int Clin Psychopharmacol. 2000;6:335–342. - PubMed
1. Greist J, Chouinard G, DuBoff E, et al. Double-blind parallel comparison of three dosages of sertraline and placebo in outpatients with obsessive-compulsive disorder. Arch Gen Psychiatry. 1995;52:289–295. - PubMed

LinkOut - more resources

Full Text Sources